Cart (0)

DCDC2B Inhibitors

DCDC2B inhibitors are characterized by their diverse chemical structures and their ability to interfere with various biochemical pathways, ultimately leading to a decrease in DCDC2B function. For instance, staurosporine, a non-selective kinase inhibitor, could reduce the functional activity of DCDC2B by impeding essential phosphorylation processes that are critical for DCDC2B's activity, assuming that DCDC2B requires phosphorylation for its function. LY 294002, a PI3K inhibitor, might indirectly diminish DCDC2B activity by attenuating the PI3K signaling cascade, which could affect phosphorylation and activation of proteins that regulate or interact with DCDC2B. Rapamycin, an inhibitor of the mTOR pathway, could disrupt processes such as protein synthesis and actin cytoskeleton organization, leading to a reduction in DCDC2B function if it is part of these cellular pathways. Additionally, cyclopamine's inhibition of the Hedgehog signaling pathway might result in a decrease in DCDC2B activity if DCDC2B is implicated in this pathway. PD 98059 and U0126 could lead to reduced DCDC2B function by preventing the activation of MEK1/2 and subsequent phosphorylation of ERK - critical steps if DCDC2B is regulated by or involved in this pathway. SB 203580, targeting p38 MAPK, and SP600125, a JNK inhibitor, could similarly decrease DCDC2B activity by altering signaling pathways that regulate or involve DCDC2B. Moreover, the effects of W-7 and 2-APB suggest that alterations in calcium signaling might also reduce DCDC2B activity, while Y-27632 could impact DCDC2B through its role in the regulation of cytoskeletal dynamics. Finally, MG-132, a proteasome inhibitor, could indirectly diminish DCDC2B levels by affecting protein degradation pathways, which may influence the functional concentration of DCDC2B in the cell. Collectively, these inhibitors, through their targeted disruption of cellular signaling and processes, could logically lead to the inhibition of DCDC2B function, despite the absence of direct evidence for such inhibition.

Items 1 to 10 of 12 total

Display:

Product Name	CAS #	Catalog #	QUANTITY	Price	Citations	RATING
Staurosporine	62996-74-1	sc-3510 sc-3510A sc-3510B	100 µg 1 mg 5 mg	$82.00 $153.00 $396.00	113	(4)
A potent non-selective kinase inhibitor that may diminish kinase-mediated phosphorylation processes crucial for the proper function of DCDC2B. If DCDC2B is a phosphoprotein, its activity could be indirectly inhibited by this compound.
LY 294002	154447-36-6	sc-201426 sc-201426A	5 mg 25 mg	$123.00 $400.00	148	(1)
A specific inhibitor of PI3K, LY 294002 could indirectly decrease DCDC2B activity if DCDC2B is downstream of PI3K signaling by reducing the phosphorylation and activation of proteins that may interact with or regulate DCDC2B.
Rapamycin	53123-88-9	sc-3504 sc-3504A sc-3504B	1 mg 5 mg 25 mg	$63.00 $158.00 $326.00	233	(4)
An mTOR inhibitor that could lead to a decrease in DCDC2B function by inhibiting mTORC1 and mTORC2 complexes, which may impact cellular processes such as protein synthesis and actin cytoskeleton organization that could involve DCDC2B.
Cyclopamine	4449-51-8	sc-200929 sc-200929A	1 mg 5 mg	$94.00 $208.00	19	(1)
A potent inhibitor of the Hedgehog signaling pathway which could indirectly reduce DCDC2B activity if DCDC2B is involved in this pathway, potentially through the modulation of cellular proliferation signals that may influence DCDC2B function.
PD 98059	167869-21-8	sc-3532 sc-3532A	1 mg 5 mg	$40.00 $92.00	212	(2)
A specific inhibitor of MEK, which could lead to diminished DCDC2B activity if the protein is regulated by the ERK/MAPK pathway, by preventing the phosphorylation and activation of downstream proteins that may interact with DCDC2B.
SB 203580	152121-47-6	sc-3533 sc-3533A	1 mg 5 mg	$90.00 $349.00	284	(5)
An inhibitor of p38 MAPK that could reduce DCDC2B activity by inhibiting p38-dependent signaling processes that may be involved in the regulation or function of DCDC2B.
U-0126	109511-58-2	sc-222395 sc-222395A	1 mg 5 mg	$64.00 $246.00	136	(2)
A selective inhibitor of MEK1/2 which could diminish DCDC2B function if DCDC2B acts downstream of the MEK/ERK pathway, by inhibiting the phosphorylation of ERK and its downstream effectors.
W-7	61714-27-0	sc-201501 sc-201501A sc-201501B	50 mg 100 mg 1 g	$166.00 $306.00 $1675.00	18	(1)
A calmodulin antagonist that could indirectly inhibit DCDC2B activity by disrupting calcium-calmodulin signaling, which may regulate various cellular processes including those that involve DCDC2B.
2-APB	524-95-8	sc-201487 sc-201487A	20 mg 100 mg	$28.00 $53.00	37	(1)
A modulator of IP3 receptors and store-operated calcium channels that could diminish the activity of DCDC2B by altering calcium signaling, potentially affecting cellular processes that DCDC2B may be involved in.
Y-27632, free base	146986-50-7	sc-3536 sc-3536A	5 mg 50 mg	$186.00 $707.00	88	(1)
A Rho-associated protein kinase inhibitor that could lead to decreased DCDC2B function by affecting cytoskeletal organization and cell motility, which may involve DCDC2B if it is associated with such cellular processes.

Santa Cruz Animal Health is a leading provider of animal health care products. ©2026 Santa Cruz Biotechnology Inc. All Rights Reserved.
Toll-Free: (800) 457-3801 - Terms & Conditions | Privacy Policy | Legal
“Santa Cruz Animal Health”, “San Juan Ranch”, the San Juan Ranch logo, “UltraCruz”, “Supplement of Champions”, are registered trademarks of Santa Cruz Biotechnology, Inc. All other trademarks are the property of their respective owners.

DCDC2B Inhibitors

Staurosporine

LY 294002

Rapamycin

Cyclopamine

PD 98059

SB 203580

U-0126

W-7

2-APB

Y-27632, free base